Antibiotics in Free Flaps Reconstructions
The Value of Perioperative Antibiotics on the Success of Oral Free Flap Reconstructions
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Design and Patient Recruitment All clinical investigations have been conducted according to the principles expressed in the Declaration of Helsinki. Patient consent was written. Any patient who required reconstructive surgery for oncological reasons within the oral cavity with microvascular free flaps was eligible. Patients receiving preoperative neoadjuvant or previous adjuvant radiation therapy in their medical history were not included in this study as the protocols available are not comparable in doses and effect on the irradiated tissue.14 A prospective study was initiated from July of 2007 to June 2012. All patients were prospectively evaluated.
Postoperative Care The investigators standard regimen was to keep the patient sedated for one night on the intensive care unit and then transfer to the surgical ward. The specific intravenous antibiotic therapy was started 30 minutes before the operation and administered for 10 days.
Data Analysis Recorded parameters included: age, sex, preoperative medical history, American society of Anesthesiologists classification of preoperative status 15, diagnosis, stage of disease, defect localisation, type of microvascular free flap, choice of recipient vessels, flap success, rate and number of operative revisions, primary or secondary reconstruction, type of previous treatment (radiation or surgery), type of previous neck dissection (if any), microvascular complications, the total operative time, wound healing disturbances subdivided into dehiscence and infection at the neck, region of reconstruction, or donor site, and prophylactic antibiotic agent, if used. Infection was defined as a purulent discharge at the wounds.
Descriptive statistics for quantitative variables are given as the mean ± standard deviation. The data were analyzed with the "Statistical Package for the Social Sciences" software (IBM® SPSS® Statistics for Windows, Version 22.0; IBM Corp., Armonk, NY, USA). Figures are generated with SPSS and Microsoft® Office Excel (Microsoft Excel for Windows, release 11.0, 2003, Microsoft Corporation, Redmond, WA, USA). Multiple linear regression analyses were used to determine factors independently associated with the dependent variable wound infection or wound healing disturbances. 95% confidence intervals (95% CI) are also given. Differences were considered to be statistically significant for a two-sided p-value of less than 0.05.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Any patient who required reconstructive surgery for oncological reasons within the oral cavity with microvascular free flaps.
Exclusion Criteria:
- Healthy humans.
- Patients receiving preoperative neoadjuvant or previous adjuvant radiation therapy in their medical history.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: control
no antibiotics
|
|
|
Active Comparator: experimental group
drug administration (antibiotic)
|
prophylactic antibiotics
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Frequencies of wound infection detected by clinical examinations (daily for 2 weeks, 2 times per week afterwards)
Time Frame: participants will be followed for the duration of hospital stay (2 weeks) and a total of 12 weeks
|
participants will be followed for the duration of hospital stay (2 weeks) and a total of 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Denys J Loeffelbein, MD, DDS, PhD, Department of Oral and Maxillofacial Surgery
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MKG-2007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postoperative Infection
-
NCT06014788RecruitingPostoperative Wound Infection Superficial Incisional | Postoperative Wound Infection Deep Incisional Surgical Site
-
NCT02731573CompletedPostoperative Wound Infection Superficial Incisional | Postoperative Wound Infection Deep Incisional Surgical Site
-
NCT05021315RecruitingPostoperative Infection | Cesarean Section Complications | Vaginal Infection
-
NCT01184430UnknownPostoperative Wound Infection | Postoperative Outcome
-
NCT02198066CompletedImpaired Wound Healing | Postoperative Wound Infection-deep
-
NCT01413659Unknown
-
NCT02280395TerminatedPost Operative Wound Infection | Postoperative Wound Infection-deep
-
NCT00290290CompletedPostoperative Wound Infection
-
NCT01212315CompletedPostoperative Wound Infection
-
NCT05676801RecruitingProsthetic Joint Infection | Surgical Site Infection | Prosthesis and Implants | Postoperative Wound Infection Deep Incisional Surgical Site
Clinical Trials on antibiotic (use of penicilline, unacid, cefuroxime)
-
NCT05002829Completed
-
NCT04334850Completed
-
NCT03919266Completed
-
NCT05378880CompletedAntimicrobial Stewardship | Drug Resistance, Bacterial
-
NCT01507974Completed
-
NCT01976065CompletedRegeneration | Pulp Necrosis
-
NCT02795949Completed
-
NCT01168063CompletedHelicobacter Pylori Infection
-
NCT03432741TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Breast Carcinoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Breast Cancer AJCC v6 and v7 | Breast Adenocarcinoma | Metastatic Breast Carcinoma